AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own CBIZ, you need to believe the Marcum acquisition and efficiency push can translate a larger, more complex platform into sustainably higher earnings, despite integration noise and pricing pressure. The latest quarter’s stronger profitability and higher EPS guidance support that view, but they do not remove the near term risk that client attrition, nonrecurring project exposure, and ongoing integration costs could still unsettle results and sentiment.
The most relevant update here is management’s reaffirmation of its 2026 revenue outlook at US$2.8 billion to US$2.9 billion, alongside higher adjusted EPS guidance. Taken together with the sizeable buybacks completed in early 2026, this suggests CBIZ is trying to balance investment in integration and technology with returning cash, which matters for a story that still hinges on converting Marcum scale and efficiency projects into durable margin improvement.
Yet against these promising numbers, investors should also keep in mind the risk that persistent pricing pressure and nonrecurring fee exposure could still...
Read the full narrative on CBIZ (it's free!)
CBIZ's narrative projects $3.0 billion revenue and $204.7 million earnings by 2029. This requires 3.3% yearly revenue growth and roughly a $50 million earnings increase from $154.3 million.
Uncover how CBIZ's forecasts yield a $43.25 fair value, a 43% upside to its current price.
The most cautious analysts were assuming revenue of about US$3.1 billion and earnings of roughly US$213.5 million by 2029, so their focus on heavy Marcum integration costs and execution risk paints a much tougher path than the consensus. This new quarter and guidance could shift those views, but it is worth recognizing how far apart expectations can be before you decide which version of CBIZ’s future you find more convincing.
Explore 2 other fair value estimates on CBIZ - why the stock might be worth over 3x more than the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com